9 Insiders Buy $45.0M in Korro Bio, Inc. (KRRO)

Nine insiders buying the same stock within a single week is rare enough to warrant attention. This isn't scattered opportunistic buying—it's coordinated conviction. The $44.9M cluster represents 37.9% of Korro Bio's $119M market cap, a concentration that moves beyond individual confidence into territory that suggests boardroom or investor-group alignment around a specific thesis.

The mechanical uniformity is striking: trades executed at a single price point ($11.11) with two repeating share quantities ($242,945 and $207,100 per transaction). Scott Sandell, Forest Baskett, Rick Yang, and Carmen Chang each deployed $5M+ in matched tranches. New Enterprise Associates 17, L.P.—a significant institutional investor—committed $5.4M across two trades. This wasn't a loose collection of independent bets. The timing, price consistency, and share-block standardization suggest a structured capital raise or financing round where insiders were given allocation rights, likely at a discount to future valuation expectations.

Price context deepens the signal. At $11.11, insiders were buying 51% below the current $23.08 level and well below the 52-week high of $24.03. This gap isn't noise—it indicates either a material recovery since these transactions or that insiders priced these purchases assuming significant upside from the entry point. For a micro-cap, which carries higher volatility and less analyst coverage, insider buying clusters during depressed valuations historically precede inflection moments: clinical trial progress, partnership announcements, or financing catalysts that restructure the company's near-term prospects.

The real weight here is collective. Individual insider purchases can reflect portfolio rebalancing or tax planning. Nine insiders buying $45M in one week, at uniform pricing, in a company representing over one-third their market cap tells a different story—one of aligned leadership and investor confidence in whatever Korro Bio's near-term catalyst may be.